LAS VEGAS, Aug. 29, 2006 (PRIMEZONE) -- Samaritan Pharmaceuticals, Inc. (AMEX:LIV) a developer of innovative drugs, announced today, its Alzheimer's research compound Caprospinol (SP-233) demonstrated no toxicity, when administered orally in an Acute Toxicity Study. Preclinical studies suggest Caprospinol (SP-233) exhibits neuroprotective properties against beta- amyloid-induced toxicity which could be indicative of a promising treatment for Alzheimer's disease.
See Caprospinol (SP-233) peer reviewed journal publications,
http://www.samaritanpharma.com/html/respublications.html
This new study, conducted in animals, supports the previous preclinical assay safety studies where Caprospinol also showed no toxic effects. In this study Caprospinol (SP-233), was given at doses of 1, 3, 10, or 30 mg/kg/day, once daily, for three consecutive days, in male and female mice, and showed no acute toxicity at the concentrations tested; and the no-observed-effect level (NOEL) was found to be 30 mg/kg, for both male and female mice.
Dr. Greeson, CEO of Samaritan Pharmaceuticals stated, "Alzheimer's is a horribly devastating disease that attacks the short-term memory first, and then destroys the brain cells until sufferers can no longer recognize their loved ones." Dr. Greeson went on to say, "We are edging real close to filing an investigational new drug application (IND) for Caprospinol with the FDA. It shouldn't be much longer; we are waiting for one additional preclinical animal study report to be audited before filing."
See NIH Alzheimer's video,
http://nihseniorhealth.gov/alzheimersdisease/defined/video/a1_qt300.html
Samaritan Pharmaceuticals: "We LIV . . . to Save Lives."
Samaritan is a small-cap Biotech, driven to discover, develop and commercialize innovative therapeutics' for AIDS, Alzheimer's, Cancer and Heart disease patients. Look at www.samaritanpharma.com. Please register on Website so we can notify you of upcoming conference calls, news and events.
The Samaritan Pharmaceuticals, Inc. logo is available at http://www.primezone.com/newsroom/prs/?pkgid=2670
Disclaimer
The company disclaims any information that is created by an outside party and endorses only information that is communicated by its press releases, filings and Website. This news release contains forward-looking statements that reflect management's current beliefs about the potential for its drug candidates, science and technology. However, as with any biopharmaceutical under development, there are significant risks and uncertainties in the process of development and regulatory review. There are no guarantees that products will prove to be commercially successful.
For additional information about the factors that affect the company's business, please read the company's latest Form 10-K filed April 13, 2006. The company undertakes no duty to update forward-looking statements.